Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4139 | Umbilical Cord Mesenchymal Stem Cells Wiki | 1.00 |
| drug2729 | Oseltamivir Wiki | 0.38 |
| drug421 | Azithromycin Wiki | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase 2 multi-center, double-blind, randomized, placebo-control clinical trial with 200 subjects who have never been infected by COVID-19 (SARS-Cov-2 virus screen test negative, no blood SARS-Cov-2 IgM and IgG antibodies detected during enrollment) followed by a pilot study of 5 subjects to demonstrate the safety of proposed three-dose regimen of autologous AdMSCs infusions. The 100 study subjects who have previously banked their AdMSCs with Celltex, will receive three doses of autologous AdMSCs (approximately 200 million cells) intravenous infusion every three days. The 100 subjects in the control group who have previously banked their AdMSCs with Celltex will not receive any Celltex's AdMSC therapy but placebo treatments. All subjects are monitored for safety (adverse events/severe adverse events), COVID-19 symptoms, SARS-Cov-2 virus test, blood SARS-Cov-2 IgM and IgG antibodies tests, blood cytokine and inflammatory (CRP, IL_6, IL-10, TNFα) tests and disease severity evaluation for 6 months after the last dose of AdMSC infusion for the study group and 6 months after the enrollment for the control group.
Description: adverse events and severe adverse events
Measure: Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication Time: 6 monthsDescription: adverse events and severe adverse events
Measure: The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group Time: 6 monthsDescription: efficacy
Measure: COVID-19 incidence rates in both the study and control groups Time: 6 monthsDescription: efficacy
Measure: The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. Time: 6 monthsDescription: efficacy
Measure: The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group. Time: 6 monthsDescription: efficacy
Measure: Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group. Time: 6 monthsDescription: efficacy
Measure: Change of lymphocyte count in white blood cell counts from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of PaO2 arterial blood gases from the baseline Time: 6 monthsDescription: efficacy
Measure: Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups Time: 6 monthsDescription: efficacy
Measure: COVID-19 mortality rates for both study and control groups Time: 6 monthsDescription: efficacy
Measure: Change of C-reactive protein (CRP) (mg/L) from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of D-dimer (mg/L) from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of Procalcitonin (ug)/L from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of Bilirubin (mg/dL) from the baseline Time: 6 monthsDescription: efficacy
Measure: Change of Creatinine (mg/dL) from the baseline Time: 6 monthsDescription: efficacy
Measure: Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline Time: 6 monthsDescription: efficacy
Measure: The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group Time: 6 monthsDescription: efficacy
Measure: Quantifying viral RNA in stool for baseline and final follow-up. Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports